Compare Gilead Sciences, Inc. (GILD) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $135.99 (market cap $168.35B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.88. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| GILD | JNK | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $98.19 |
52-Week Low | $110.56 | $94.66 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
JNK trades at $95.845, up 0.2% today, with a bearish technical outlook indicated by moving averages and ADX signals. Recent news highlights risks from AI-related corporate debt and rising Treasury yields, while dividend payments provide income. The ETF faces headwinds from inflation and geopolitical tensions affecting bond markets.
The outlook is cautious due to credit market risks and Fed uncertainty. Opportunities exist for yield-seeking investors, but volatility from oil prices and rate hikes poses significant risks. Monitoring economic data and corporate credit health is essential for navigating near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
